Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.
2024年7月1日，美國總部的全球臨床生物製藥公司致力於通過T細胞驅動的研究開發治療慢性炎症性疾病的療法，Connect Biopharma Holdings Limited（納斯達克：CNTB）公佈Barry Quart（首席執行官）、David Szekeres（總裁）和Steven Chan（首席財務官）將於2024年7月9日至10日在馬薩諸塞州波士頓舉行的Leerink Partners Inflammation and Immunology（I＆I）和Metabolism Therapeutics Forum上舉行一對一投資者會議。
About Connect Biopharma Holdings Limited
關於Connect Biopharma Holdings Limited
Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and drug discovery to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company's second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/
Connect Biopharma是一家全球性的臨床階段生物製藥公司，應用其在T細胞生物學和藥物發現方面的專長，開發創新的療法治療慢性炎症性疾病，旨在改善全球數百萬患者的生活。公司正在建立一條專有的小分子和抗體管道，利用功能性T細胞測定屏幕和發現針對驗證的免疫靶點的強效產品候選物。公司的領先產品候選rademikibart（以前稱爲CBP-201）是一種抗體，旨在靶向在發展中的過敏性皮炎和哮喘中的白細胞介素-4受體α（IL-4Rα）。公司的第二個產品候選icanbelimod（以前稱爲CBP-307）是S1P1T細胞受體的調節劑，用於潰瘍性結腸炎（UC）的治療。欲了解更多信息，請訪問：https://www.connectbiopharm.com/
INVESTOR CONTACT:
投資者聯繫方式：
Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com
蒂姆·麥卡錫
LifeSci Advisors
tim@lifesciadvisors.com
譯文內容由第三人軟體翻譯。